Although antibody-mediated blockade of the PD-1/PD-L1 interaction is an effective clinical strategy in several tumor types, data from trials in mCRPC patients suggest that PD-1/PD-L1 blockade is less effective in this disease, with no observable objective responses after nivolumab treatment [57]. The gene discussed is CD274; the disease is neoplasm.